Infectious diseases and critical care conditions continue to pose some of the most formidable challenges in modern medicine. The increasing prevalence of antimicrobial resistance and the complexity of critical illnesses demand a new generation of therapies that combine speed, precision, and proven clinical efficacy.

YasellePharmaceuticals established the Anti-Infectives & Critical Care Division – YaselleZyntrix to address these life-threatening therapeutic needs through innovation and scientific rigor. The name “Zyntrix” is derived from “Zyn” (life/catalyst) and “Trix” (protector), representing our mission to safeguard life through resilient and responsive therapy solutions. This division reflects Mandara’s unwavering commitment to protecting patients in moments that matter most, by delivering evidence-based, reliable, and life-saving treatments.